复星医药子公司复迈宁新增适应症临床试验获批准

Group 1 - The core announcement is that Fosun Pharma's subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., has received approval from the National Medical Products Administration to conduct clinical trials for the drug Rumaine (generic name: Luwomeitini tablets) in combination with Anlotinib for advanced non-small cell lung cancer (NSCLC) patients with KRAS mutations [1] - The company plans to initiate Phase II clinical trials for this drug in China once conditions are met [1] - The drug has already been approved for two indications in China, including treatment for Langerhans cell histiocytosis (LCH) and adult patients with tissue tumors, as well as for pediatric and adolescent patients aged 2 years and older with symptomatic, inoperable plexiform neurofibromas (PN) associated with type 1 neurofibromatosis (NF1) [1]